Although the antibodies of PD-1/PD-L1 have shown improving outcome in patients with melanoma, renal cell carcinoma, non-small lung cancer, the results of treating pancreatic cancer with single-agent immune checkpoint inhibitors have been disappointing [10–13]. Here, CD274 is linked to pancreatic neoplasm.